> Some investors are unhappy about the pay packages of UK biotech execs. Report
> Israel's Can-Fite has inked a new licensing deal with Japan's Seikagaku for the development of CF-101 as a therapy for RA and other inflammatory diseases. Report
> Scottish entrepreneur Sir Tom Hunter has taken a 20 percent stake in Merlin Biosciences, a UK life sciences investment group. The stake is believed to have cost around 15 million pounds sterling. Merlin has gathered more than a billion pounds for life science investments in the past nine years. Report
> The UK's Innovata has reached a settlement in its legal dispute with Pall Corp. Report
And Finally… Russia's improving economy is spurring big growth in the country's use of pharmaceuticals. Article (WSJ sub. req.)